Intellia - Margin operasi NTLA

Logo korporat perusahaan Intellia (NTLA)

The CRISPR patent foundation promises Intellia Therapeutics (NTLA) long-term leadership in the therapy of rare pathologies, as evidenced by the ebit margin dynamics. The value -821.20 characterizes this valuation parameter. The application of AI and robotics accelerates drug synthesis, although final tests require expert control. Breakthrough developments in the treatment of hereditary diseases are currently shaping the future profit cycle.

intelliatx.com (NTLA): Margin bathi operasi saka 04.07.2022 nganti 20.11.2026

Rincian analitis lan laporan data perusahaan Intellia Therapeutics, Inc. (NTLA)

- rega lan prakiraan konsensus rega:
Pambiji fundamental:Intellia Corp, NTLA
Produk merek intelliatx.com

Operating margin measures cost management efficiency, showing the share of profit from core operations before accounting for financial expenses and taxes. For Intellia Therapeutics (NTLA), this metric reflects the cost of developing CRISPR therapies and the expenses associated with the safe disposal of laboratory resources. Analyzing the business's operating margin allows for an assessment of the biotech's ability to scale its research. The indicator's trend reveals the real cost of the innovation cycle. It is critical for investors to benchmark these values against product commercialization rates.

Analisis pesaing

Margin dodolan operasi TEM|QGEN - Tingkat bathi adhedhasar bathi operasi|Margin operasi IONS|RGEN - Rentabilitas dodolan operasi|Rentabilitas operasi Avidity RNA|Margin operasi CRISPR Therapeutics Corp CRSP|GeneDx Corp - Margin operasi|Ultragenyx Pharma (RARE) - Margin dodolan operasi|beamtx.com (BEAM) - Rentabilitas operasi|SRPT: Rasio bathi operasi|Margin dodolan operasi TWST|TXG - Tingkat bathi adhedhasar bathi operasi|Rentabilitas operasi Stoke Corp (STOK)|Rentabilitas kegiatan operasi BioLife|Margin operasi WVE (Wave Life Sciences Ltd)|MAZE: Rentabilitas dodolan miturut bathi operasi|Sionna Therapeutics, Inc. - Margin operasi|Tingkat bathi operasi PRME (Prime Medicine Inc)|TSHA (Taysha Gene Therapies, Inc.) - Margin dodolan operasi|QURE - Rentabilitas kegiatan operasi|MGTX (MeiraGTx Corp) - Margin operasi|Rentabilitas dodolan operasi REGENXBIO Inc. RGNX|Rentabilitas operasi Solid Biosciences (SLDB)|Ocugen Corp - Rentabilitas dodolan miturut bathi operasi|Rentabilitas operasi Pacific Biosciences PACB|Rasio bathi operasi BNTC (Benitec)|Design Corp - Margin operasi|Rocket Pharmaceuticals - Rasio bathi operasi|Rentabilitas dodolan miturut bathi operasi 4D Molecular Therapeutics, Inc.|Rentabilitas dodolan operasi Lexeo Therapeutics (LXEO)|KRRO (Korro Bio, Inc.) - Margin operasi|Rentabilitas dodolan operasi Editas EDIT|Margin operasi SLN|ProQR Therapeutics - Rentabilitas dodolan miturut bathi operasi|Margin operasi CDXS (Codexis, Inc.)|SGMO: Rentabilitas dodolan miturut bathi operasi|Nautilus Biotechnology - Margin operasi|Tingkat bathi operasi MGX (Metagenomi, Inc)|DTIL: Margin operasi|GBIO: Rasio bathi operasi|Rentabilitas operasi Boundless Bio Inc.|Margin dodolan operasi Exicure (XCUR)|Margin operasi IMNN|PHIO (Phio Pharmaceuticals Corp.) - Tingkat bathi operasi|Mustang Bio, Inc. - Margin dodolan operasi|RNAZ - Margin dodolan operasi|BNGO: Margin dodolan operasi|APDN (Applied DNA Sciences Inc) - Rentabilitas dodolan miturut bathi operasi|BLUE (Bluebird Bio) - Margin dodolan operasi|ImmunoPrecise Antibodies Ltd - Tingkat bathi operasi|OMGA (Omega Therapeutics Inc) - Margin operasi|Rentabilitas operasi OMIC|Rentabilitas operasi Regulus Therapeutics Inc. (RGLS)|Margin dodolan operasi Syros Pharmaceuticals, Inc. SYRS|Telesis Bio - Margin dodolan operasi|Tingkat bathi operasi TCON|UBX - Rentabilitas operasi